<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Selective IgA deficiency: Management and prognosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Selective IgA deficiency: Management and prognosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Selective IgA deficiency: Management and prognosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert W Hostoffer, DO, LhD, MSMed, MBA, FACOP, FAAP, FACOI, FCCP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jordan S Orange, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION AND DEFINITION</span><span class="headingEndMark"> — </span>Selective immunoglobulin A (IgA) deficiency (sIgAD; MIM 137100) is defined as the isolated deficiency of serum IgA (ie, serum levels of immunoglobulin G [IgG] and immunoglobulin M [IgM] are normal) in a patient older than four years of age in whom other causes of hypogammaglobulinemia have been excluded. It is the most common primary antibody defect in humans.</p><p class="bulletIndent1"><span class="glyph">●</span>Severe IgA deficiency refers to serum levels below 7 mg/dL, which is the lower limit of detection for most assays.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Partial IgA deficiency refers to serum levels above 7 mg/dL but below the lower limit of normal (ie, lower than 2 standard deviations below the age-adjusted mean).</p><p></p><p>Note that some experts do not distinguish severe and partial deficiencies and reserve the diagnosis of IgA deficiency for patients with levels below 7 mg/dL [<a href="#rid1">1,2</a>].</p><p>The clinical manifestations of sIgAD range from an asymptomatic laboratory finding to recurrent infections and autoimmune disease. This topic reviews the management and prognosis of patients with sIgAD. The clinical features, pathophysiology, and diagnosis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3963.html" rel="external">"Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis"</a>.)</p><p class="headingAnchor" id="H24165524"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>All individuals with sIgAD should not only be informed about the associated conditions but also reassured that the majority of people with this laboratory finding are healthy and live normal lives.</p><p class="headingAnchor" id="H88323150"><span class="h2">Review medications</span><span class="headingEndMark"> — </span>Several medications are associated with IgA deficiency (eg, antiseizure medications, <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a>, certain nonsteroidal antiinflammatory drugs, etc), and efforts to discontinue these medications should be made. A more detailed discussion of the drugs associated with IgA deficiency is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3963.html" rel="external">"Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis", section on 'Drug-induced immunoglobulin disorders'</a>.)</p><p class="headingAnchor" id="H17790881"><span class="h2">Vaccinations</span><span class="headingEndMark"> — </span>The following recommendations concern vaccination of patients with sIgAD:</p><p class="bulletIndent1"><span class="glyph">●</span>For asymptomatic individuals with partial IgA deficiency, there are no special restrictions for vaccine use.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with severe sIgAD, certain live-viral vaccines are contraindicated because patients with humoral immunodeficiencies can develop disseminated infections. Specifically, oral polio vaccine, Bacille Calmette-Guérin, and yellow fever should <strong>not</strong> be given, especially in those with associated IgG subclass deficiency [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients in whom the diagnosis of sIgAD is preliminary because an immune evaluation is incomplete, a more cautious approach is warranted, and live local vaccines (eg, intranasal influenza and live rotavirus) should also be avoided until the evaluation is complete. These additional restrictions are warranted because IgA deficiency can be a finding in other, more severe immunodeficiencies (eg, ataxia-telangiectasia), which preclude a wider array of live vaccines.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other vaccines, such as the pneumococcal vaccine, are specifically recommended for patients with sIgAD to help reduce the risk of sinopulmonary infections [<a href="#rid3">3</a>].</p><p></p><p class="headingAnchor" id="H17790957"><span class="h2">Asymptomatic patients</span><span class="headingEndMark"> — </span>Most people with partial IgA deficiency are asymptomatic. These individuals require no specific treatment beyond education. Patients with severe sIgAD are less likely to be entirely asymptomatic, although this is still possible. If an asymptomatic person with severe sIgAD has received blood products at any point, then they should be checked for anti-IgA antibodies.</p><p class="headingAnchor" id="H17790888"><span class="h3">Monitoring</span><span class="headingEndMark"> — </span>There is no consensus about how asymptomatic patients should be monitored. The approach of the author and editors of UpToDate is to ask patients to return at periodic intervals to review the frequency of infections, as well as a thorough review of systems. We also suggest checking levels of IgA, IgG, and IgM periodically.</p><p class="headingAnchor" id="H6"><span class="h2">Symptomatic patients</span><span class="headingEndMark"> — </span>Symptomatic patients with sIgAD are managed according to the disorder present.</p><p class="headingAnchor" id="H8"><span class="h3">Sinopulmonary infections</span><span class="headingEndMark"> — </span>The most common clinical manifestation of symptomatic sIgAD is recurrent sinopulmonary infections or recurrent otitis media in younger children, which may impact the patient's full participation in life (school, job, social functioning). Patients may benefit from several interventions to prevent or reduce the frequency of these illnesses, such as treatment of concomitant rhinitis or asthma, prophylactic antibiotics, or, if these measures are insufficient, <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> therapy.</p><p class="headingAnchor" id="H9"><span class="h4">Treat concomitant disorders</span><span class="headingEndMark"> — </span>The finding of sIgAD in a patient with recurrent infections does not exclude other causes of sinopulmonary infections. Patients with sIgAD may also have chronic rhinosinusitis, allergic rhinitis/asthma, or chronic nonallergic rhinitis. These other conditions could be more important causes of recurrent infection. (See  <a class="medical medical_review" href="/z/d/html/7528.html" rel="external">"Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management"</a> and  <a class="medical medical_review" href="/z/d/html/7532.html" rel="external">"Chronic nonallergic rhinitis"</a>.)</p><p class="headingAnchor" id="H10"><span class="h4">Prophylactic antibiotics</span><span class="headingEndMark"> — </span>For patients with continued infections despite management of underlying conditions, a six-month course of daily prophylactic antibiotics can be instituted. Maintenance prophylactic antibiotics may be continued if the initial course is successful. It may also be possible to administer these antibiotics only during the winter, depending upon the patient's historic pattern of infections. The use of prophylactic antibiotics in inborn errors of immunity is reviewed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/3948.html" rel="external">"Inborn errors of immunity (primary immunodeficiencies): Overview of management", section on 'Prophylactic antimicrobial therapy'</a>.)</p><p class="headingAnchor" id="H11"><span class="h4">Immune globulin</span><span class="headingEndMark"> — </span>A trial of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> replacement therapy may occasionally be warranted in patients with recurrent infections if prophylactic antibiotics fail to diminish the number of infections, particularly if there is an associated antibody deficiency and/or subclass deficiency. In our experience, only a small minority of patients with sIgAD require immune globulin to control infections. This therapy does not replete IgA in the serum or secretions but rather provides pathogen-specific IgG pooled from the general adult population.</p><p><a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">Immune globulin</a> replacement may be administered intravenously or subcutaneously  (<a class="graphic graphic_table graphicRef116460" href="/z/d/graphic/116460.html" rel="external">table 1</a>). Anaphylaxis to subcutaneous immune globulin (SCIG) is rare. A potential complication of intravenous therapy in sIgA-deficient patients is the presence of anti-IgA antibodies that may cause anaphylaxis [<a href="#rid4">4-9</a>]. To reduce this risk, intravenous preparations with the lowest content of IgA should be utilized whenever possible  (<a class="graphic graphic_table graphicRef116460" href="/z/d/graphic/116460.html" rel="external">table 1</a>). The use of immune globulin in patients with immunodeficiency is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3942.html" rel="external">"Subcutaneous and intramuscular immune globulin therapy"</a> and  <a class="medical medical_review" href="/z/d/html/4431.html" rel="external">"Overview of intravenous immune globulin (IVIG) therapy"</a> and  <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">"Intravenous immune globulin: Adverse effects", section on 'Preparation'</a>.)</p><p class="headingAnchor" id="H18735965"><span class="h3"><i>Giardia</i> infection</span><span class="headingEndMark"> — </span>Patients with sIgAD can become infected with <em>Giardia lamblia</em> from contaminated private wells, public sources, and bottled water. The clinical manifestations and diagnosis of acute and chronic infection are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/5723.html" rel="external">"Giardiasis: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p>Measures to reduce <em>Giardia</em> exposure through drinking water are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6024.html" rel="external">"Giardiasis: Treatment and prevention", section on 'Counseling and prevention'</a>.)</p><p class="headingAnchor" id="H2380121283"><span class="h3">COVID-19 infection</span><span class="headingEndMark"> — </span>It is unclear whether sIgAD patients experience a more severe illness course with infection of coronavirus disease 2019 (COVID-19). One small study looking at 11 patients with sIgAD and COVID-19 infection showed a 7.7 fold higher risk of severe disease compared with controls [<a href="#rid10">10</a>]. In another larger cohort of 772 patients with sIgAD with matched controls who were observed over 34 months, sIgAD was associated with higher rates of COVID-19 infection and reinfection [<a href="#rid11">11</a>]. This may have been due to a diminished mucosal IgA presence, although larger studies are necessary [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H1732469"><span class="h3">Autoimmune disorders</span><span class="headingEndMark"> — </span>The management of patients with sIgAD and autoimmune disease is dictated by the autoimmune disorder present. Associated autoimmune disorders are reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3963.html" rel="external">"Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis", section on 'Autoimmune disorders and autoantibodies'</a>.)</p><p>The management of autoimmune diseases is discussed in various topic reviews. (See  <a class="medical medical_review" href="/z/d/html/4675.html" rel="external">"Overview of the management and prognosis of systemic lupus erythematosus in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6400.html" rel="external">"Systemic juvenile idiopathic arthritis: Treatment"</a>.)</p><p class="headingAnchor" id="H6475461"><span class="h3">Reactions to blood products</span><span class="headingEndMark"> — </span>Patients with <strong>severe</strong> sIgAD (ie, undetectable serum IgA) can experience infusion reactions to blood products containing small amounts of IgA, typically in plasma, including the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Whole blood</p><p class="bulletIndent1"><span class="glyph">●</span>Red blood cells</p><p class="bulletIndent1"><span class="glyph">●</span>Platelets</p><p class="bulletIndent1"><span class="glyph">●</span>Fresh frozen plasma</p><p class="bulletIndent1"><span class="glyph">●</span>Cryoprecipitate</p><p class="bulletIndent1"><span class="glyph">●</span>Granulocytes</p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (although immune globulin contains very low amounts of IgA compared with other products above)</p><p></p><p>Anti-IgA antibodies have been identified in severely IgA-deficient patients who experienced infusion reactions to blood products and have been implicated as the cause of these infusion reactions, although it has not been conclusively demonstrated that these antibodies cause the reactions [<a href="#rid13">13</a>]. Indirect evidence in support of the role of anti-IgA antibodies includes the finding that these antibodies are more prevalent in patients with sIgAD who have experienced anaphylaxis compared with those who have not (76 compared with 22 percent in one study of approximately 200 patients) [<a href="#rid14">14</a>].</p><p>There are two types of anti-IgA antibodies, which are IgG and IgE, and both may be implicated in adverse reactions to blood products [<a href="#rid9">9,13,15,16</a>]. IgE anti-IgA is much less common than IgG anti-IgA. IgE anti-IgA was demonstrated in only 1 individual in a series of 46 IgA-deficient patients, and this individual had life-threatening anaphylaxis in response to intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> [<a href="#rid6">6</a>]. Despite these uncertainties, the diagnosis of IgA-related anaphylaxis is usually assumed if a patient experiences infusion-related anaphylaxis and has undetectable serum IgA combined with anti-IgA antibodies of either type.</p><p>Most patients with sIgAD do not form anti-IgA antibodies. These antibodies are usually only found in patients with undetectable serum IgA. Even among severely IgA-deficient individuals, antibodies to IgA are rare. In studies of blood donors, anti-IgA antibodies where detected in severely IgA-deficient patients at a frequency of approximately 1 in 1200 to 1600 [<a href="#rid14">14,17</a>]. (See  <a class="medical medical_review" href="/z/d/html/3963.html" rel="external">"Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis", section on 'Anaphylactic reactions to blood products'</a>.)</p><p>In the past, assays for anti-IgA antibodies were time consuming and limited to research or blood bank laboratories [<a href="#rid18">18</a>]. However, a commercial assay is available for the detection of IgG against IgA [<a href="#rid19">19,20</a>]. There is no commercial test for IgE anti-IgA, but a positive test for the IgG isotype assumes that the patient might also be capable of producing IgE against IgA. </p><p class="headingAnchor" id="H24166158"><span class="h4">Indications for screening for anti-IgA antibodies</span><span class="headingEndMark"> — </span>We suggest screening for anti-IgA antibodies in all patients with severe sIgAD and in patients with partial sIgAD who have experienced an infusion reaction to a blood product in the past. Screening for anti-IgA antibodies allows clinicians to identify patients at risk for infusion reactions and helps these patients become informed about the potential risks of receiving blood products.</p><p class="headingAnchor" id="H24166165"><span class="h4">Preparation for future treatment</span><span class="headingEndMark"> — </span>Patients with severe sIgAD, either with or without positive screening tests for anti-IgA antibodies (as patients with negative screens can become sensitized over time), are advised to obtain a medical alert bracelet/necklace inscribed with the following information:</p><p class="bulletIndent1"><span class="glyph">●</span>The patient has sIgAD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient is at risk for an allergic reaction to any injected plasma-containing blood products, and testing for anti-IgA antibodies should be performed before such blood products are administered.</p><p></p><p class="headingAnchor" id="H24166172"><span class="h4">Safe administration of blood products</span><span class="headingEndMark"> — </span>All blood products should be used with caution in IgA-deficient patients, and appropriate staff and medication should be available to treat anaphylaxis [<a href="#rid21">21</a>].</p><p>Patients who have already experienced an infusion reaction to plasma-containing blood products should be tested for anti-IgA antibodies prior to receiving any additional blood products. If positive, a strategy should be devised for safe administration of future blood products. The approach will differ depending upon the blood product needed. Consultation with a transfusion medicine specialist should be considered [<a href="#rid22">22</a>]. Examples include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients who require transfusions of red blood cells can receive cells that have been washed to remove as much of the contaminating IgA as possible [<a href="#rid18">18,19,23</a>]. (See  <a class="medical medical_review" href="/z/d/html/7947.html" rel="external">"Immunologic transfusion reactions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who require <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> therapy can receive products that are low in IgA content or receive the therapy subcutaneously. (See  <a class="medical medical_review" href="/z/d/html/3942.html" rel="external">"Subcutaneous and intramuscular immune globulin therapy", section on 'IgA-deficient patients'</a>.)</p><p></p><p>Desensitization to blood products is another approach that may be appropriate in specific circumstances. A case report described desensitization of a patient with sIgAD who experienced anaphylaxis to blood products but subsequently required numerous infusions of various blood products in the context of liver transplant. The patient was successfully desensitized to an <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> preparation, which was then administered weekly to maintain the desensitized state [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H13"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The prognosis of sIgAD is not well studied, although studies have found the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Severe sIgAD in children usually persists, whereas partial sIgAD in children may resolve over time, particularly if no other inborn error of immunity is present [<a href="#rid25">25-27</a>]. This was demonstrated in a study that followed 40 children with severe sIgAD and 40 with partial deficiency [<a href="#rid27">27</a>]. At four years after initial diagnosis, serum levels remained low in those with severe deficiency but had risen to normal in one-half of those with partial deficiency.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>sIgAD can progress to common variable immunodeficiency [<a href="#rid28">28-33</a>]. This tended to occur in adolescence or young adulthood in the available case reports. (See  <a class="medical medical_review" href="/z/d/html/3963.html" rel="external">"Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis", section on 'Pathophysiology of IgA deficiency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The prognosis of IgA deficiency diagnosed in adulthood is not well studied, and it is not known if the condition spontaneously remits in a subset of individuals.</p><p></p><p>Data indicating that the severity of sIgAD (ie, serum IgA levels) impacts prognosis are lacking. Ultimately, prognosis probably depends largely upon the presence and severity of associated disorders or progression of the immunodeficiency.</p><p class="headingAnchor" id="H17790741"><span class="h2">Risk of malignancy</span><span class="headingEndMark"> — </span>Patients with sIgAD have been determined to have a moderately increased risk of cancer, particularly involving the gastrointestinal tract. The risk was found more significant in adults than children [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H782760954"><span class="h2">Risk of neurologic disorders</span><span class="headingEndMark"> — </span>In one large study, there was an increased prevalence of neurologic disorders such as epilepsy, autism spectrum disorders, and tics in patients with sIgAD compared with a matched control patient population, suggesting a cause-and-effect relationship between these neurologic disorders and sIgAD [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H3471777663"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112831.html" rel="external">"Society guideline links: Inborn errors of immunity (previously called primary immunodeficiencies)"</a>.)</p><p class="headingAnchor" id="H24165556"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>Information for patients about sIgAD is available online through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fprimaryimmune.org%2Funderstanding-primary-immunodeficiency%2Ftypes-of-pi%2Fselective-iga-deficiency&amp;token=nnX3eGZJ47%2FNFRl%2BnrkjNI0ZFIe9%2B%2BLSbgRJCqvArQvgw%2BKbn3NMiBTb0Dj6JzpcXWMrkjx8o8xb2GHsZX6SOBNJC0mXbuzD3l4VLpgpF6%2FOwf0jYCW9vxE7R1sNhO50&amp;TOPIC_ID=3936" target="_blank">Immune Deficiency Foundation</a> [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Selective immunoglobulin A (IgA) deficiency (sIgAD; MIM 137100) may be defined as the selective deficiency of serum IgA (ie, serum levels of immunoglobulin G [IgG] and immunoglobulin M [IgM] are normal) in a patient older than four years of age in whom other causes of hypogammaglobulinemia have been excluded. (See <a class="local">'Introduction and definition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Most patients are asymptomatic</strong> – The majority of patients with sIgAD are asymptomatic. These patients require only education about the condition and periodic monitoring. (See <a class="local">'Asymptomatic patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disorders in symptomatic patients</strong> – Symptomatic patients with sIgAD most commonly suffer from recurrent sinopulmonary infections, autoimmune disorders, gastrointestinal disorders, and/or associated immunodeficiencies. Anaphylactic transfusion reactions to plasma-containing blood products can occur, although these are rare. (See <a class="local">'Symptomatic patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and management of sinopulmonary infections</strong> – Patients with recurrent sinopulmonary symptoms should be evaluated and treated for other conditions predisposing to upper respiratory tract infections (eg, allergic rhinitis/asthma, chronic rhinosinusitis). (See <a class="local">'Treat concomitant disorders'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients who continue to have sinopulmonary infections despite aggressive management of predisposing conditions (eg, allergic rhinitis/asthma, chronic rhinosinusitis), we suggest a trial of prophylactic antibiotics (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Prophylactic antibiotics'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with recurrent sinopulmonary infections, clearly impaired vaccine responses, and no improvement with prophylactic antibiotics, we suggest a trial of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> replacement therapy to reduce the number and severity of infections (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). An intravenous or subcutaneous preparation that is low in IgA content is preferred. (See <a class="local">'Immune globulin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Caution with blood products</strong> – In patients with undetectable levels of serum IgA and in those with past infusion reactions to plasma-containing blood products, we perform a baseline screening test for anti-IgA antibodies to better assess patients' risk for future infusion reactions to blood products. If these antibodies are identified, various steps can be taken to prevent recurrent reactions, depending upon the blood product needed. (See <a class="local">'Reactions to blood products'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Severe sIgAD appears to be a lasting condition, while partial sIgAD sometimes resolves, particularly in children. The risk of malignancy is moderately increased in adults with IgA deficiency. The prognosis of patients with sIgAD probably depends largely upon the presence and severity of associated disorders. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="headingAnchor" id="H933938711"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges E Richard Stiehm, MD, who contributed as a Section Editor to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol 2015; 136:1186.</a></li><li><a class="nounderline abstract_t">Tangye SG, Al-Herz W, Bousfiha A, et al. Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 2022; 42:1473.</a></li><li class="breakAll">American Academy of Pediatrics. Immunization and other considerations in immunocompromised children. In: Red Book: 2018 Report of the Committee on Infectious Diseases, 31st ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Itasca, IL 2018. p.72.</li><li><a class="nounderline abstract_t">Cunningham-Rundles C, Zhou Z, Mankarious S, Courter S. Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies. J Clin Immunol 1993; 13:272.</a></li><li><a class="nounderline abstract_t">Björkander J, Hammarström L, Smith CI, et al. Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. J Clin Immunol 1987; 7:8.</a></li><li><a class="nounderline abstract_t">Ferreira A, Garcia Rodriguez MC, Lopez-Trascasa M, et al. Anti-IgA antibodies in selective IgA deficiency and in primary immunodeficient patients treated with gamma-globulin. Clin Immunol Immunopathol 1988; 47:199.</a></li><li><a class="nounderline abstract_t">Sandler SG, Mallory D, Malamut D, Eckrich R. IgA anaphylactic transfusion reactions. Transfus Med Rev 1995; 9:1.</a></li><li><a class="nounderline abstract_t">Vassallo RR. Review: IgA anaphylactic transfusion reactions. Part I. Laboratory diagnosis, incidence, and supply of IgA-deficient products. Immunohematology 2004; 20:226.</a></li><li><a class="nounderline abstract_t">Horn J, Thon V, Bartonkova D, et al. Anti-IgA antibodies in common variable immunodeficiency (CVID): diagnostic workup and therapeutic strategy. Clin Immunol 2007; 122:156.</a></li><li><a class="nounderline abstract_t">Çölkesen F, Kandemir B, Arslan Ş, et al. Relationship between Selective IgA Deficiency and COVID-19 Prognosis. Jpn J Infect Dis 2022; 75:228.</a></li><li><a class="nounderline abstract_t">Magen E, Merzon E, Green I, et al. Selective IgA deficiency and COVID-19. J Allergy Clin Immunol Pract 2023; 11:1936.</a></li><li><a class="nounderline abstract_t">Quinti I, Mortari EP, Fernandez Salinas A, et al. IgA Antibodies and IgA Deficiency in SARS-CoV-2 Infection. Front Cell Infect Microbiol 2021; 11:655896.</a></li><li><a class="nounderline abstract_t">Rachid R, Bonilla FA. The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature. J Allergy Clin Immunol 2012; 129:628.</a></li><li><a class="nounderline abstract_t">Sandler SG, Eckrich R, Malamut D, Mallory D. Hemagglutination assays for the diagnosis and prevention of IgA anaphylactic transfusion reactions. Blood 1994; 84:2031.</a></li><li><a class="nounderline abstract_t">Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N Engl J Med 1986; 314:560.</a></li><li><a class="nounderline abstract_t">Rachid R, Castells M, Cunningham-Rundles C, Bonilla FA. Association of anti-IgA antibodies with adverse reactions to γ-globulin infusion. J Allergy Clin Immunol 2011; 128:228.</a></li><li><a class="nounderline abstract_t">Palmer DS, O'Toole J, Montreuil T, et al. Screening of Canadian Blood Services donors for severe immunoglobulin A deficiency. Transfusion 2010; 50:1524.</a></li><li><a class="nounderline abstract_t">Yuan S, Goldfinger D. A readily available assay for anti-immunoglobulin A: is this what we have been waiting for? Transfusion 2008; 48:2048.</a></li><li><a class="nounderline abstract_t">Brown R, Nelson M, Aklilu E, et al. An evaluation of the DiaMed assays for immunoglobulin A antibodies (anti-IgA) and IgA deficiency. Transfusion 2008; 48:2057.</a></li><li class="breakAll">ID-PaGIA Anti-IgA antibody test: information available at www.diamed.com (Accessed on September 13, 2010).</li><li><a class="nounderline abstract_t">Chowdary P, Nair D, Davies N, et al. Anaphylactic reaction with prothrombin complex concentrate in a patient with IgA deficiency and anti-IgA antibodies. Blood Coagul Fibrinolysis 2010; 21:764.</a></li><li><a class="nounderline abstract_t">Davenport RD, Burnie KL, Barr RM. Transfusion management of patients with IgA deficiency and anti-IgA during liver transplantation. Vox Sang 1992; 63:247.</a></li><li><a class="nounderline abstract_t">Meena-Leist CE, Fleming DR, Heye M, Herzig RH. The transfusion needs of an autologous bone marrow transplant patient with IgA deficiency. Transfusion 1999; 39:457.</a></li><li><a class="nounderline abstract_t">Kiani-Alikhan S, Yong PF, Grosse-Kreul D, et al. Successful desensitization to immunoglobulin A in a case of transfusion-related anaphylaxis. Transfusion 2010; 50:1897.</a></li><li><a class="nounderline abstract_t">Joller PW, Buehler AK, Hitzig WH. Transitory and persistent IgA deficiency. Reevaluation of 19 pediatric patients once found to be deficient in serum IGA. J Clin Lab Immunol 1981; 6:97.</a></li><li><a class="nounderline abstract_t">Blum PM, Hong R, Stiehm ER. Spontaneous recovery of selective IgA deficiency. Additional case reports and a review. Clin Pediatr (Phila) 1982; 21:77.</a></li><li><a class="nounderline abstract_t">Plebani A, Ugazio AG, Monafo V, Burgio GR. Clinical heterogeneity and reversibility of selective immunoglobulin A deficiency in 80 children. Lancet 1986; 1:829.</a></li><li><a class="nounderline abstract_t">Aghamohammadi A, Mohammadi J, Parvaneh N, et al. Progression of selective IgA deficiency to common variable immunodeficiency. Int Arch Allergy Immunol 2008; 147:87.</a></li><li><a class="nounderline abstract_t">Español T, Catala M, Hernandez M, et al. Development of a common variable immunodeficiency in IgA-deficient patients. Clin Immunol Immunopathol 1996; 80:333.</a></li><li><a class="nounderline abstract_t">Gutierrez MG, Kirkpatrick CH. Progressive immunodeficiency in a patient with IgA deficiency. Ann Allergy Asthma Immunol 1997; 79:297.</a></li><li><a class="nounderline abstract_t">Slyper AH, Pietryga D. Conversion of selective IgA deficiency to common variable immunodeficiency in an adolescent female with 18q deletion syndrome. Eur J Pediatr 1997; 156:155.</a></li><li><a class="nounderline abstract_t">Litzman J, Burianova M, Thon V, Lokaj J. Progression of selective IgA deficiency to common variable immunodeficiency in a 16 year old boy. Allergol Immunopathol (Madr) 1996; 24:174.</a></li><li><a class="nounderline abstract_t">Hostoffer RW, Bay CA, Wagner K, et al. Kabuki make-up syndrome associated with an acquired hypogammaglobulinemia and anti-IgA antibodies. Clin Pediatr (Phila) 1996; 35:273.</a></li><li><a class="nounderline abstract_t">Ludvigsson JF, Neovius M, Ye W, Hammarström L. IgA deficiency and risk of cancer: a population-based matched cohort study. J Clin Immunol 2015; 35:182.</a></li><li><a class="nounderline abstract_t">Magen E, Geishin A, Merzon E, et al. Prevalence of neurological diseases among patients with selective IgA deficiency. Allergy Asthma Proc 2023; 44:e17.</a></li><li class="breakAll">Information for patients about selective IgA deficiency is available online and free of charge through the Immune Deficiency Foundation. https://primaryimmune.org/about-primary-immunodeficiencies/specific-disease-types/selective-iga-deficiency/ (Accessed on September 28, 2017).</li></ol></div><div id="topicVersionRevision">Topic 3936 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26371839" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Practice parameter for the diagnosis and management of primary immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35748970" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35748970" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8227286" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3494039" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2450712" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Anti-IgA antibodies in selective IgA deficiency and in primary immunodeficient patients treated with gamma-globulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7719037" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : IgA anaphylactic transfusion reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15679454" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Review: IgA anaphylactic transfusion reactions. Part I. Laboratory diagnosis, incidence, and supply of IgA-deficient products.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17137841" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Anti-IgA antibodies in common variable immunodeficiency (CVID): diagnostic workup and therapeutic strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34588364" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Relationship between Selective IgA Deficiency and COVID-19 Prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36858279" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Selective IgA deficiency and COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33889552" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : IgA Antibodies and IgA Deficiency in SARS-CoV-2 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21835445" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8081004" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Hemagglutination assays for the diagnosis and prevention of IgA anaphylactic transfusion reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3945295" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21397310" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Association of anti-IgA antibodies with adverse reactions toγ-globulin infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20158683" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Screening of Canadian Blood Services donors for severe immunoglobulin A deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18928505" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A readily available assay for anti-immunoglobulin A: is this what we have been waiting for?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18657081" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : An evaluation of the DiaMed assays for immunoglobulin A antibodies (anti-IgA) and IgA deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18657081" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : An evaluation of the DiaMed assays for immunoglobulin A antibodies (anti-IgA) and IgA deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20885296" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Anaphylactic reaction with prothrombin complex concentrate in a patient with IgA deficiency and anti-IgA antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1481472" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Transfusion management of patients with IgA deficiency and anti-IgA during liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10335993" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The transfusion needs of an autologous bone marrow transplant patient with IgA deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20456696" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Successful desensitization to immunoglobulin A in a case of transfusion-related anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7288875" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Transitory and persistent IgA deficiency. Reevaluation of 19 pediatric patients once found to be deficient in serum IGA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7056010" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Spontaneous recovery of selective IgA deficiency. Additional case reports and a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2870316" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clinical heterogeneity and reversibility of selective immunoglobulin A deficiency in 80 children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18520152" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Progression of selective IgA deficiency to common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8811056" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Development of a common variable immunodeficiency in IgA-deficient patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9357373" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Progressive immunodeficiency in a patient with IgA deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9039524" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Conversion of selective IgA deficiency to common variable immunodeficiency in an adolescent female with 18q deletion syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8939274" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Progression of selective IgA deficiency to common variable immunodeficiency in a 16 year old boy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8804548" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Kabuki make-up syndrome associated with an acquired hypogammaglobulinemia and anti-IgA antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25589342" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : IgA deficiency and risk of cancer: a population-based matched cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37641224" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Prevalence of neurological diseases among patients with selective IgA deficiency.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
